Oct. 30 Quick Takes: Q32 raises B round; plus CStone-LegoChem, Centrexion, Sidekick
Q32 raises $60M series B round, starts first clinical trial
Immunology company Q32 Bio Inc. raised $60 million in a series B round led by OrbiMed Advisors and Acorn Bioventures, with participation from Osage University Partners, Atlas Venture, Abingworth, Sanofi Ventures, University of Colorado and Children’s Hospital Colorado Center for Innovation. The company also began a Phase I trial of IL-7R antibody ADX-914 to treat autoimmune disorders. Atlas led Q32’s $46 million series A round in 2018.
CStone adds innovative preclinical ADC program
CStone Pharmaceuticals Co. Ltd. (HKEX:2616) licensed exclusive rights outside of South Korea for a preclinical antibody-drug conjugate targeting ROR1 from LegoChem Biosciences Inc. (KOSDAQ:141080). LegoChem will receive $10 million up front and up to $353.3 million in milestones plus tiered royalties for rights to LCB71. There are no ADCs targeting ROR1 on the market, but at least three are in clinical development...